| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study
|
Lowenthal, Elizabeth D
|
|
|
|
4 |
p. e222-e232
|
artikel
|
| 2 |
Access to medicines: lessons from the HIV response
|
Vella, Stefano
|
|
2017
|
|
4 |
p. e147-e149
nvt p.
|
artikel
|
| 3 |
Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial
|
Priddy, Frances H
|
|
2019
|
|
4 |
p. e230-e239
|
artikel
|
| 4 |
A focus on disability is necessary to achieve HIV epidemic control
|
Kuper, Hannah
|
|
|
|
4 |
p. e293-e298
|
artikel
|
| 5 |
Ageing with HIV: is the virus or the treatment guilty?
|
Capeau, Jacqueline
|
|
|
|
4 |
p. e182-e183
|
artikel
|
| 6 |
Andrey Rylkov Foundation for Health and Social Justice
|
Holt, Ed
|
|
2019
|
|
4 |
p. e219
|
artikel
|
| 7 |
Antiretroviral gels: facing the FACTS
|
The Lancet HIV,
|
|
2015
|
|
4 |
p. e115-
1 p.
|
artikel
|
| 8 |
Are toxicities of current nucleosides still a concern?
|
Vivancos, Maria J
|
|
2018
|
|
4 |
p. e156-e157
|
artikel
|
| 9 |
Are we ready for long-acting HIV treatment for adolescents?
|
Rakhmanina, Natella
|
|
|
|
4 |
p. e200-e201
|
artikel
|
| 10 |
A rich tapestry of stories
|
Ranscombe, Peter
|
|
|
|
4 |
p. e228
|
artikel
|
| 11 |
Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis
|
Kelly, Helen
|
|
|
|
4 |
p. e262-e278
|
artikel
|
| 12 |
Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study
|
Hernández-Ramírez, Raúl U
|
|
2019
|
|
4 |
p. e240-e249
|
artikel
|
| 13 |
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
|
Sax, Paul E
|
|
2017
|
|
4 |
p. e154-e160
nvt p.
|
artikel
|
| 14 |
Brain not exempt from social determinants of health
|
Monnig, Mollie A
|
|
|
|
4 |
p. e212-e213
|
artikel
|
| 15 |
Building African HIV networks in the UK HIV response
|
Lucas, Catherine
|
|
|
|
4 |
p. e210
|
artikel
|
| 16 |
Commitment needed from South Africa's new president
|
The Lancet HIV,
|
|
2018
|
|
4 |
p. e155
|
artikel
|
| 17 |
Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative study
|
Solomon, Sunil Suhas
|
|
2016
|
|
4 |
p. e183-e190
nvt p.
|
artikel
|
| 18 |
Community viral load as an index of HIV transmission potential
|
Herbeck, Joshua
|
|
2016
|
|
4 |
p. e152-e154
nvt p.
|
artikel
|
| 19 |
Corrections
|
|
|
2015
|
|
4 |
p. e126-
1 p.
|
artikel
|
| 20 |
Corrections
|
|
|
2015
|
|
4 |
p. e126-
1 p.
|
artikel
|
| 21 |
Cost-effectiveness of community-based strategies for HIV
|
Abu-Raddad, Laith J
|
|
2015
|
|
4 |
p. e122-e123
nvt p.
|
artikel
|
| 22 |
Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis
|
Smith, Jennifer A
|
|
2015
|
|
4 |
p. e159-e168
nvt p.
|
artikel
|
| 23 |
Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study
|
Sharma, Monisha
|
|
|
|
4 |
p. e216-e224
|
artikel
|
| 24 |
Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis
|
Suthar, Amitabh B
|
|
2015
|
|
4 |
p. e137-e150
nvt p.
|
artikel
|
| 25 |
Co-trimoxazole prophylaxis: the debates continue
|
Badri, Motasim
|
|
2015
|
|
4 |
p. e118-e119
nvt p.
|
artikel
|
| 26 |
Declaration commits to ending AIDS in children
|
The Lancet HIV,
|
|
|
|
4 |
p. e209
|
artikel
|
| 27 |
Defining principles for a choice-based approach to HIV prevention
|
Williams, Katie M
|
|
|
|
4 |
p. e269-e272
|
artikel
|
| 28 |
Delayed presentation of HIV among older individuals: a growing problem
|
Justice, Amy C
|
|
|
|
4 |
p. e269-e280
|
artikel
|
| 29 |
Delivery of anti-HIV bNAbs by viral vectors
|
Caskey, Marina
|
|
2019
|
|
4 |
p. e207-e208
|
artikel
|
| 30 |
Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis
|
Zhang, Jing
|
|
|
|
4 |
p. e254-e268
|
artikel
|
| 31 |
Disputed figures do not hide Russia's HIV epidemic
|
Holt, Ed
|
|
2019
|
|
4 |
p. e216-e217
|
artikel
|
| 32 |
Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial
|
Vanbaelen, Thibaut
|
|
|
|
4 |
p. e233-e244
|
artikel
|
| 33 |
Effects of clinical, comorbid, and social determinants of health on brain ageing in people with and without HIV: a retrospective case-control study
|
Petersen, Kalen J
|
|
|
|
4 |
p. e244-e253
|
artikel
|
| 34 |
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
|
Gallant, Joel E
|
|
2016
|
|
4 |
p. e158-e165
nvt p.
|
artikel
|
| 35 |
Ending AIDS by 2030: catchy slogan or sincere goal?
|
Braithwaite, R Scott
|
|
2018
|
|
4 |
p. e160-e161
|
artikel
|
| 36 |
Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial
|
Esteban-Cantos, Andrés
|
|
|
|
4 |
p. e197-e205
|
artikel
|
| 37 |
Escaping the shadow of the tombstone
|
Ranscombe, Peter
|
|
2019
|
|
4 |
p. e220
|
artikel
|
| 38 |
Ethical trial design for the future
|
The Lancet HIV,
|
|
|
|
4 |
p. e181
|
artikel
|
| 39 |
Evidence with 95-95-95 that ambitious is feasible
|
Maheu-Giroux, Mathieu
|
|
|
|
4 |
p. e203-e204
|
artikel
|
| 40 |
Extended-release opioid antagonists and HIV treatment
|
Lee, Joshua D
|
|
2019
|
|
4 |
p. e206-e207
|
artikel
|
| 41 |
Fate of people with HIV in jeopardy in Ukraine
|
The Lancet HIV,
|
|
|
|
4 |
p. e223
|
artikel
|
| 42 |
Fear and stigma in Kenya
|
Burki, Talha
|
|
|
|
4 |
p. e232
|
artikel
|
| 43 |
FLAMINGO: still in the pink?
|
Barber, Tristan J
|
|
2015
|
|
4 |
p. e116-e117
nvt p.
|
artikel
|
| 44 |
GBD 2017 and HIV estimates for Taiwan
|
Lo, Yi-Chun
|
|
|
|
4 |
p. e224
|
artikel
|
| 45 |
GBD 2017 and HIV estimates for Taiwan – Authors' reply
|
Kyu, Hmwe Hmwe
|
|
|
|
4 |
p. e224-e225
|
artikel
|
| 46 |
Good news for retention of women on option B+ in Malawi
|
Sibanda, Euphemia L
|
|
2016
|
|
4 |
p. e151-e152
nvt p.
|
artikel
|
| 47 |
Health equity for Black sexually minoritised men through status-neutral HIV care
|
Pagkas-Bather, Jade
|
|
|
|
4 |
p. e268-e272
|
artikel
|
| 48 |
Helping hospitals heal people with HIV and tuberculosis
|
Reuter, Anja
|
|
|
|
4 |
p. e224-e225
|
artikel
|
| 49 |
Highlights of the first virtual CROI
|
Hayward, Peter
|
|
|
|
4 |
p. e227
|
artikel
|
| 50 |
Highlights of the 26th CROI 2019
|
Hayward, Peter
|
|
2019
|
|
4 |
p. e218
|
artikel
|
| 51 |
Highlights of the 30th CROI
|
Hayward, Peter
|
|
|
|
4 |
p. e219
|
artikel
|
| 52 |
Highlights of virtual CROI 2022
|
Hayward, Peter
|
|
|
|
4 |
p. e231
|
artikel
|
| 53 |
Highlights of virtual CROI 2021
|
Hayward, Peter
|
|
|
|
4 |
p. e184
|
artikel
|
| 54 |
High volume subcutaneous delivery of long-acting HIV bNAbs
|
Caskey, Marina
|
|
|
|
4 |
p. e211-e212
|
artikel
|
| 55 |
HIV and cardiovascular disease
|
So-Armah, Kaku
|
|
|
|
4 |
p. e279-e293
|
artikel
|
| 56 |
HIV and disabilities: time for more and better data
|
Tun, Waimar
|
|
2017
|
|
4 |
p. e143-e144
nvt p.
|
artikel
|
| 57 |
HIV funders need to shift power and resources to communities
|
Thompson, Healy
|
|
|
|
4 |
p. e216
|
artikel
|
| 58 |
HIV in transgender women in Brazil
|
Poteat, Tonia
|
|
2017
|
|
4 |
p. e144-e146
nvt p.
|
artikel
|
| 59 |
HIV testing approaches to reach the first UNAIDS 95% target in sub-Saharan Africa
|
Chamie, Gabriel
|
|
|
|
4 |
p. e225-e236
|
artikel
|
| 60 |
HIV treatment and anal cancer: emerging clarity
|
Jin, Fengyi
|
|
|
|
4 |
p. e220-e221
|
artikel
|
| 61 |
How health systems can adapt to a population ageing with HIV and comorbid disease
|
Kiplagat, Jepchirchir
|
|
|
|
4 |
p. e281-e292
|
artikel
|
| 62 |
Indications for starting ART
|
Mussini, Cristina
|
|
2018
|
|
4 |
p. e157-e158
|
artikel
|
| 63 |
Integrase inhibitors go head-to-head
|
Barber, Tristan
|
|
2017
|
|
4 |
p. e142-e143
nvt p.
|
artikel
|
| 64 |
International Women's Day—how can I help?
|
Orkin, Chloe
|
|
|
|
4 |
p. e228-e229
|
artikel
|
| 65 |
Is HIV-1C a risk factor for protease inhibitor failure?
|
van Zyl, Gert U
|
|
2016
|
|
4 |
p. e149-e151
nvt p.
|
artikel
|
| 66 |
Is sub-Saharan Africa ready for pre-exposure prophylaxis?
|
Bernier, Adeline
|
|
2016
|
|
4 |
p. e154-e155
nvt p.
|
artikel
|
| 67 |
Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data
|
Schaefer, Robin
|
|
|
|
4 |
p. e242-e253
|
artikel
|
| 68 |
Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial
|
Pitisuttithum, Punnee
|
|
|
|
4 |
p. e238-e248
|
artikel
|
| 69 |
Lessons on PrEP from the SEARCH study in east Africa
|
Celum, Connie
|
|
|
|
4 |
p. e219-e220
|
artikel
|
| 70 |
Like London buses, two putative cure cases arrive at once
|
The Lancet HIV,
|
|
2019
|
|
4 |
p. e205
|
artikel
|
| 71 |
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
|
Orkin, Chloe
|
|
|
|
4 |
p. e185-e196
|
artikel
|
| 72 |
Long-acting PrEP: new opportunities with some drawbacks
|
Xiridou, Maria
|
|
|
|
4 |
p. e213-e215
|
artikel
|
| 73 |
Maintenance of antiretroviral efficacy in children
|
Cotton, Mark F
|
|
2015
|
|
4 |
p. e120-e121
nvt p.
|
artikel
|
| 74 |
Making PrEP easy
|
Marcus, Julia L
|
|
|
|
4 |
p. e226-e228
|
artikel
|
| 75 |
Migration and risk of HIV acquisition in Rakai, Uganda: a population-based cohort study
|
Olawore, Oluwasolape
|
|
2018
|
|
4 |
p. e181-e189
|
artikel
|
| 76 |
Migration patterns and HIV prevention in Uganda
|
Nöstlinger, Christiana
|
|
2018
|
|
4 |
p. e158-e160
|
artikel
|
| 77 |
Neglected risk factors for HIV and Toxoplasma gondii co-infection
|
Chen, Jin
|
|
2017
|
|
4 |
p. e151-e152
nvt p.
|
artikel
|
| 78 |
Neglected risk factors for HIV and Toxoplasma gondii co-infection
|
Abdoli, Amir
|
|
2017
|
|
4 |
p. e152-
1 p.
|
artikel
|
| 79 |
Neglected risk factors for HIV and Toxoplasma gondii co-infection – Authors' reply
|
Wei, Feng
|
|
2017
|
|
4 |
p. e152-e153
nvt p.
|
artikel
|
| 80 |
Neuropsychiatric symptoms in Tanzanian HIV-infected children receiving long-term efavirenz treatment: a multicentre, cross-sectional, observational study
|
Van de Wijer, Lisa
|
|
2019
|
|
4 |
p. e250-e258
|
artikel
|
| 81 |
New insights are game-changers in HIV-2 disease management
|
Hingrat, Quentin Le
|
|
2019
|
|
4 |
p. e214
|
artikel
|
| 82 |
New insights are game-changers in HIV-2 disease management – Authors' reply
|
Esbjörnsson, Joakim
|
|
2019
|
|
4 |
p. e214-e215
|
artikel
|
| 83 |
Non-Hodgkin lymphoma in people with HIV
|
Aboulafia, David M
|
|
2019
|
|
4 |
p. e209-e210
|
artikel
|
| 84 |
Not just PrEP: other reasons for London's HIV decline
|
Nwokolo, Nneka
|
|
2017
|
|
4 |
p. e153-
1 p.
|
artikel
|
| 85 |
Novel metric for evaluating pre-exposure prophylaxis programme effectiveness in real-world settings
|
Hendrickson, Cheryl
|
|
|
|
4 |
p. e294-e300
|
artikel
|
| 86 |
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study
|
Molina, Jean-Michel
|
|
2015
|
|
4 |
p. e127-e136
nvt p.
|
artikel
|
| 87 |
Optimising PrEP uptake and use in Peru: no time to lose!
|
Menacho, Luis
|
|
|
|
4 |
p. e204-e206
|
artikel
|
| 88 |
Outcomes after viral load rebound on first-line antiretroviral treatment in children with HIV in the UK and Ireland: an observational cohort study
|
Childs, Tristan
|
|
2015
|
|
4 |
p. e151-e158
nvt p.
|
artikel
|
| 89 |
Point-of-care HIV testing can help achieve UNAIDS targets
|
Hellard, Margaret
|
|
|
|
4 |
p. e216-e217
|
artikel
|
| 90 |
Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial
|
Drain, Paul K
|
|
|
|
4 |
p. e229-e237
|
artikel
|
| 91 |
Point-of-care testing to achieve paediatric 95-95-95 targets
|
Peter, Trevor F
|
|
|
|
4 |
p. e210-e211
|
artikel
|
| 92 |
Preconception ART and preterm birth: real effect or selection bias?
|
Stringer, Jeffrey S A
|
|
2017
|
|
4 |
p. e150-
1 p.
|
artikel
|
| 93 |
Preconception ART and preterm birth: real effect or selection bias? – Authors' reply
|
Nachega, Jean B
|
|
2017
|
|
4 |
p. e150-e151
nvt p.
|
artikel
|
| 94 |
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study
|
Smith, Jennifer
|
|
|
|
4 |
p. e254-e265
|
artikel
|
| 95 |
PrEParing to curb the HIV epidemic in Zambia
|
The Lancet HIV,
|
|
|
|
4 |
p. e199
|
artikel
|
| 96 |
Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis
|
Wang, Ze-Dong
|
|
2017
|
|
4 |
p. e177-e188
nvt p.
|
artikel
|
| 97 |
Prevalence of HIV infection among people with disabilities: a population-based observational study in Yaoundé, Cameroon (HandiVIH)
|
De Beaudrap, Pierre
|
|
2017
|
|
4 |
p. e161-e168
nvt p.
|
artikel
|
| 98 |
Progress towards the UNAIDS 95-95-95 targets in the Fifth Botswana AIDS Impact Survey (BAIS V 2021): a nationally representative survey
|
Mine, Madisa
|
|
|
|
4 |
p. e245-e254
|
artikel
|
| 99 |
Providers should discuss U=U with all patients living with HIV
|
Calabrese, Sarah K
|
|
2019
|
|
4 |
p. e211-e213
|
artikel
|
| 100 |
Real-world safety of pre-exposure prophylaxis for HIV
|
Burns, Charles M
|
|
|
|
4 |
p. e225-e226
|
artikel
|
| 101 |
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting
|
Julg, Boris
|
|
2019
|
|
4 |
p. e259-e268
|
artikel
|
| 102 |
Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study
|
Haas, Andreas D
|
|
2016
|
|
4 |
p. e175-e182
nvt p.
|
artikel
|
| 103 |
Rethinking HIV pre-exposure prophylaxis prevention strategy
|
Kistan, Jesne
|
|
2016
|
|
4 |
p. e155-e157
nvt p.
|
artikel
|
| 104 |
Risk compensation and STI incidence in PrEP programmes
|
Quaife, Matthew
|
|
|
|
4 |
p. e222-e223
|
artikel
|
| 105 |
Russia's invasion of Ukraine threatens HIV response
|
Holt, Ed
|
|
|
|
4 |
p. e230
|
artikel
|
| 106 |
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial
|
Mahomed, Sharana
|
|
|
|
4 |
p. e230-e243
|
artikel
|
| 107 |
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
|
Gaur, Aditya H
|
|
|
|
4 |
p. e211-e221
|
artikel
|
| 108 |
Should efavirenz be used in children and, if so, how?
|
Cotton, Mark F
|
|
2019
|
|
4 |
p. e210-e211
|
artikel
|
| 109 |
Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial
|
Krupitsky, Evgeny
|
|
2019
|
|
4 |
p. e221-e229
|
artikel
|
| 110 |
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
|
Winston, Alan
|
|
2018
|
|
4 |
p. e162-e171
|
artikel
|
| 111 |
Tenofovir alafenamide: safer, but questions remain
|
Boyd, Mark A
|
|
2016
|
|
4 |
p. e148-e149
nvt p.
|
artikel
|
| 112 |
The case for prescribing PrEP in community mental health settings
|
Sudler, Andrew
|
|
|
|
4 |
p. e237-e244
|
artikel
|
| 113 |
The conference of the future today?
|
The Lancet HIV,
|
|
|
|
4 |
p. e215
|
artikel
|
| 114 |
The effect of the Xpert HIV-1 Qual test on early infant diagnosis of HIV in Myanmar and Papua New Guinea: a pragmatic, cluster-randomised, stepped-wedge, open-label trial
|
Mohamed, Yasmin
|
|
|
|
4 |
p. e220-e229
|
artikel
|
| 115 |
The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS
|
Kelly, Sherrie L
|
|
2018
|
|
4 |
p. e190-e198
|
artikel
|
| 116 |
The need for a health equity framework in next-generation pre-exposure prophylaxis implementation
|
Valente, Pablo K
|
|
|
|
4 |
p. e266-e268
|
artikel
|
| 117 |
The other C word
|
The Lancet HIV,
|
|
2017
|
|
4 |
p. e141-
1 p.
|
artikel
|
| 118 |
The potential effect of COVID-19-related disruptions on HIV incidence and HIV-related mortality among men who have sex with men in the USA: a modelling study
|
Mitchell, Kate M
|
|
|
|
4 |
p. e206-e215
|
artikel
|
| 119 |
Three in five over 50s receiving late HIV diagnoses in the UK
|
Kirby, Tony
|
|
|
|
4 |
p. e226
|
artikel
|
| 120 |
Toxoplasma gondii and HIV: a never-ending story
|
Nissapatorn, Veeranoot
|
|
2017
|
|
4 |
p. e146-e147
nvt p.
|
artikel
|
| 121 |
Treatment-as-prevention and HIV incidence in men who have sex with men
|
Wijstma, Eline S
|
|
|
|
4 |
p. e207
|
artikel
|
| 122 |
Treatment-as-prevention and HIV incidence in men who have sex with men – Authors' reply
|
Callander, Denton
|
|
|
|
4 |
p. e207-e208
|
artikel
|
| 123 |
Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis
|
Dhana, Ashar
|
|
|
|
4 |
p. e233-e241
|
artikel
|
| 124 |
UK emergency department testing for HIV expanded
|
Kirby, Tony
|
|
|
|
4 |
p. e209
|
artikel
|
| 125 |
UK HIV transmission drops in the wake of COVID-19
|
Kirby, Tony
|
|
|
|
4 |
p. e217-e218
|
artikel
|
| 126 |
Uncovering HIV and malaria interactions: the latest evidence and knowledge gaps
|
Figueroa-Romero, Antía
|
|
|
|
4 |
p. e255-e267
|
artikel
|
| 127 |
UNGASS: time to put HIV at the forefront of drug policy
|
The Lancet HIV,
|
|
2016
|
|
4 |
p. e147-
1 p.
|
artikel
|
| 128 |
Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, Brazil
|
Grinsztejn, Beatriz
|
|
2017
|
|
4 |
p. e169-e176
nvt p.
|
artikel
|
| 129 |
Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study
|
Koss, Catherine A
|
|
|
|
4 |
p. e249-e261
|
artikel
|
| 130 |
Vaccine boosts: balancing response magnitude and character
|
Crowley, Andrew R
|
|
|
|
4 |
p. e217-e219
|
artikel
|
| 131 |
Viral co-infections in high-risk communities of Pakistan
|
Shah, Adil A
|
|
2015
|
|
4 |
p. e124-e125
nvt p.
|
artikel
|
| 132 |
Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden
|
Häggblom, Amanda
|
|
2016
|
|
4 |
p. e166-e174
nvt p.
|
artikel
|
| 133 |
Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial
|
Molina, Jean-Michel
|
|
2018
|
|
4 |
p. e172-e180
|
artikel
|
| 134 |
Who benefits from frequent asymptomatic STI screening?
|
Medland, Nicholas
|
|
|
|
4 |
p. e201-e202
|
artikel
|
Tijdschrift beschrijving